Last updated: 2026-09-06 13:05:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Creative Medical Technology Holdings, Inc. (CELZ) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $1.12, with a market capitalization of $7.45M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.62 to $6.25. This page covers its latest market performance, valuation, price trends and company information.
$7.45M | |
$1.06 | |
$51.45 | |
$0.62 | |
$1.06 | |
149.53K | |
-- | |
-- | |
$6.25 | |
$0.62 | |
-- | |
-- |
Creative Medical Technology Holdings, Inc. (CELZ) last closed at $1.06 as of 2026-09-04 23:51:00, unchanged from the previous close of $1.06.
During the latest regular trading session, CELZ traded between $0.62 and $51.45, with a volume of 149.53K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Creative Medical Technology Holdings, Inc. (CELZ) moved from $1.14 to $1.12, representing a decline of 2.19% ($0.02).
The stock traded between $1.06 and $1.12 during the period. The latest price is near the upper end of the 7-day range, indicating moderate downward.
The average daily volume was 175.45 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 8.8%
CELZ is currently trading at $1.12, placing it 8.8% of the way from its 52-week low of $0.62 to its 52-week high of $6.25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 4 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Creative Medical Technology Holdings, Inc. (CELZ) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.